Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Recurrent Malignant Glioma With a Hypermutator Phenotype
NCT02658279Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2016
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of pembrolizumab in glioma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Objective Response Rate at 1 year. Started Jan 2016; status: active, not recruiting.
02
Drugs
03
Conditions
glioma
Beyond the preview
Go deeper on NCT02658279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02658279.